US and European physicians wary of using biosimilars without clinical data backing
The majority of US and European physicians are wary of using a biosimilar for an indication for which supporting clinical data are lacking, according to the findings of a new report from advisory firm Decision Resources titled Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties.
It is estimated that more than 40 biosimilars are currently in development, and that the first branded biologics to face competition from the new generics will be those used in the treatment of cancer and rheumatoid arthritis. Europe has already approved several biosimilars, but the USA is still working on a pathway for Food and Drug Administration clearance of such copies of biological products.
French doctors most conservative
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze